CXCL10 antagonism and plasma sDPPIV in chronic HCV patients

CXCL10 (also known as interferon-gamma induced protein 10 or IP-10) has been investigated in the context of HCV disease pathogenesis and noted to be a negative predictor of response to pegylated interferon / ribavirin (peg-IFN / RBV) therapy. We have previously reported that circulating CXCL10 in HCVg1 patients is catabolized by the enzyme dipeptidyl peptidase IV (DPPIV; also known as CD26), generating an antagonist form of CXCL10. These results clarified the correlation with treatment failure, and introduced the possibility of inhibiting DPPIV as a mechanism of enhancing treatment response.


We investigated the role of CXCL10-mediated chemokine antagonism in 70 chronic HCVg4 Egyptian patients. Our aim was to extend our prior data and validate DPPIV as a potential therapeutic target in Egyptian patients. We determined the concentration of different forms of CXCL10 (total, agonist, and antagonist) and evaluated plasma soluble DPPIV (sDPPIV) concentration and plasma dipeptidylpeptidase (DPP) activity. Analyses are on-going and will be available soon.


Back to on-going & planned research work


Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union